Literature DB >> 8482364

Hepatic apolipoprotein B synthesis in copper-deficient rats.

F Nassir1, A Mazur, C Sérougne, E Gueux, Y Rayssiguier.   

Abstract

The present study was designed to examine if induction of apolipoprotein B synthesis is associated with hypercholesterolemia in copper-deficient rats. This hypercholesterolemia mainly resides in an increase in the HDL-1 and LDL and is associated with a significant increase in plasma apoB concentration. Liver apoB mRNA levels were not significantly modified in deficient animals as compared to control rats. Studies on liver apolipoprotein synthesis indicated that apoB100 synthesis was increased in deficient animals whereas apoB48 synthesis was unchanged. Thus, it appears that the increase in apoB synthesis in the liver of copper-deficient rats occurs at the posttranscriptional level. The selective increase in apoB100 synthesis indicates the possible impact of this deficiency on the editing of apoB. An increase in apoB100 synthesis by the liver in copper-deficient rats may significantly contribute to the increase in plasma concentration of LDL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482364     DOI: 10.1016/0014-5793(93)81105-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Increased hepatic synthesis and accumulation of plasma apolipoprotein B100 in copper-deficient rats does not result from modification in apolipoprotein B mRNA editing.

Authors:  F Nassir; F Giannoni; A Mazur; Y Rayssiguier; N O Davidson
Journal:  Lipids       Date:  1996-04       Impact factor: 1.880

2.  Apolipoprotein A-I, A-IV and E synthesis in the liver of copper-deficient rats.

Authors:  F Nassir; A Mazur; E Gueux; C Sérougne; Y Rayssiguier
Journal:  Lipids       Date:  1994-10       Impact factor: 1.880

3.  ATP7B knockout disturbs copper and lipid metabolism in Caco-2 cells.

Authors:  Sarah Guttmann; Oksana Nadzemova; Inga Grünewald; Malte Lenders; Eva Brand; Andree Zibert; Hartmut H Schmidt
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.